Vanadium and the cardiovascular functions

Canadian Journal of Physiology and Pharmacology

Volumn 82, Issue 10, 2004, Pages 833-839

  Coderre, Lise ^a   Srivastava, Ashok K ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Glucose transport; Insulin signaling pathway; Smooth muscle contractility; Vanadium compounds

Indexed keywords

CALCIUM ION; GLUCOSE TRANSPORTER 4; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; VANADIUM; VANADIUM DERIVATIVE;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CONFERENCE PAPER; ENZYME ACTIVATION; ENZYME INHIBITION; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HEART MUSCLE CONTRACTILITY; HUMAN; HYPERTENSION; INSULIN RESPONSE; METAL METABOLISM; NONHUMAN; PHOSPHOINOSITIDE METABOLISM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR PHYSIOLOGY; HUMANS; MUSCLE, SMOOTH, VASCULAR; VANADIUM; VASOCONSTRICTION;

EID: 13544264560     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y04-089     Document Type: Conference Paper

References (76)

1. Almira, B.C., Garcia, A.R., and Boshell, B.R. 1986. Insulin binding and glucose transport activity in cardiomyocytes of a diabetic rat. Am. J. Physiol. 250: E402-E406.
2. Barbagallo, M., Dominguez, L.J., and Resnick, L.M. 2001. Insulin-mimetic action of vanadate. Role of intracellular magnesium. Hypertension, 38: 701-704.
3. Barbagallo, M., Dominguez, L.J., Galioto, A., Ferlisi, A., Calogero, C., Malfa, L. et al. 2003. Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. Mol. Asp. Med. 24: 39-52.
4. Bhanot, S., and McNeill, J.H. 1994. Vanadyl sulfate lowers plasma insulin and blood pressure in spontaneously hypertensive rats. Hypertension, 24: 625-632.
5. Bhanot, S., Bryer-Ash, M., Cheung, A., and McNeill, J.H. 1994a. Bis (maltolato) oxovanadium (IV) attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats. Diabetes, 43: 857-861.
6. Bhanot, S., McNeill, J.H., and Bryer-Ash, M. 1994b. Vanadyl sulfate prevents fructose-induced hyperinsulinemia and hypertension in rats. Hypertension, 23: 308-312.
7. Bhanot, S., Michoulas, A., and McNeill, J.H. 1995. Antihypertensive effects of vanadium compounds in hyperinsulinemic, hypertensive rats. Mol. Cell. Biochem. 153: 205-209.
8. Boscolo, P., Carmignani, M., Volpe, A.R., Felaco, M., Del Rosso, L., Porcelli, L., and Giuliano, G. 1994. Renal toxicity and arterial hypertension in rats chronically exposed to vanadate. Occup. Environ. Med. 51: 500-503.
9. Brazil, D.P., and Hemmings, B. 2001. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem. Sci. 26: 657-664.
10. Bryant, N.J., Govers, R., and James, D.E. 2002. Regulated transport of the glucose transporter GLUT-4. Nat. Rev. Mol. Cell Biol. 3: 267-277.
11. Byrne, A.R., and Kosta, L. 1978. Vanadium in foods and in human body fluids and tissues. Sci. Total Environ. 10: 17-30.
12. Cam, M.C., Brownsey, R.W., and McNeill, J.H. 2000. Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent? Can. J. Physiol. Pharmacol. 78: 829-847.
13. Candura, S.M., Manzo, L., Marraccini, P., Coccini, T., and Tonini, M. 1993. Investigation into vanadate-induced potentiation of smooth muscle contractility in the rabbit isolated ileum. Life Sci. 54: 237-244.
14. Chasteen, N.D. 1983. The biochemistry of vanadium. In Structure and bonding. Springer Verlag, Berlin and Heidelberg 53, pp. 105-208.
15. D'Onofrio, F., Le, M.Q., Chiasson, J.L., and Srivastava, A.K. 1994. Activation of mitogen activated protein (MAP) kinases by vanadate is independent of insulin receptor autophosphorylation. FEBS Lett. 340: 269-275.
16. Di Salvo, J., Semenchuk, L.A., and Lauer, J. 1993. Vanadate-induced contraction of smooth muscle and enhanced protein tyrosine phosphorylation. Arch. Biochem. Biophys. 304: 386-391.
17. Donthi, R.U., Huisamen, B., and Lochner, A. 2000. Effect of vanadate and insulin on glucose transport in isolated adult rat cardiomyocytes. Cardiovasc. Drugs Ther. 14: 463-470.
18. Ferrannini, E., and Natali, A. 1991. Essential hypertension, metabolic disorders and insulin resistance. Am. Heart J. 121: 1274-1282.
19. French, R.J., and Jones, P.J.H. 1992. Role of vanadium in nutrition: metabolism, essentiality and dietary consideration. Life Sci. 52: 339-346.
20. Fruman, D.A., Meyers, R.E., and Cantley, L.C. 1998. Phosphoinoside kinase. Ann Rev. Biochem. 67: 481-507.
21. Garvey, W.T., Hardin, D., Juhaszova, M., and Dominguez, J.H. 1993. Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy. Am. J. Physiol. 264: H837-H844.
22. Genet, S., Kale, R.K., and Baquer, N.Z. 1999. Effects of vanadate, insulin and fenugreek (Trigonella foenum graecum) on creatine kinase levels in tissues of diabetic rat. Indian J. Exp. Biol. 37: 200-202.
23. Genet, S., Kale, R.K., and Baquer, N.Z. 2002. Alterations in antioxidant enzymes and oxidative damage in experimental diabetic rat tissues: effect of vanadate and fenugreek (Trigonella foenum graecum). Mol. Cell. Biochem. 236: 7-12.
24. Heyliger, C.E., Tahilliani, A.G., and McNeill, J.H. 1985. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science, 277: 1474-1477.
25. Hopfner, R.L., Misurski, D.A., McNeill, J.R., and Gopalkrishnan, V. 1999. Effect of sodium orthovanadate treatment on cardiovascular function in the hyperinsulinemic, insulin-resistant obese Zucker rat. J. Cardiovasc. Pharmacol. 34: 811-817.
26. Hudgins, P.M., and Bond, G.H. 1981. Alteration by vanadate of contractility in vascular and intestinal smooth muscle preparations. Pharmacology, 23: 156-164.
27. Huisamen, B. 2003. Protein kinase B in the diabetic heart. Mol. Cell. Biochem. 249: 31-38.
28. Huisamen, B., Donthi, R.V., and Lochner, A. 2001. Insulin in combination with vanadate stimulates glucose transport in isolated cardiomyocytes from obese Zucker rats. Cardiovasc. Drugs Ther. 15: 445-452.
29. Huyer, G., Liu, S., Kelly, J., Moffat, J., Payette, P., Kennedy, B. et al. 1997. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J. Biol. Chem. 272: 843-851.
30. Inciarte, D.J., Steffen, R.P., Dobbins, D.E., Swindall, B.T., Johnston, J., and Haddy, F.J. 1980. Cardiovascular effects of vanadate on the dog. Am. J. Physiol. 239: H47-H56.
31. Kopp, S.J., Daar, J., Paulson, D.J., Romano, F.D., and Laddaga, R. 1997. Effects of oral vanadyl treatment on diabetes-induced alterations in the heart GLUT-4 transporter. J. Mol. Cell. Cardiol. 29: 2355-2362.
32. Kumar, A., and Corder, C.N. 1980. Diuretic and vasoconstrictor effects of sodium orthovanadate on the isolated perfused rat kidney. J. Pharmacol. Exp. Ther. 213: 85-90.
33. Laniyonu, A., Saifeddin, M., Ahmad, S., and Hollenberg, M.D. 1994. Regulation of vascular and gastric smooth muscle contractility by pervanadate. Br. J. Pharmacol. 113: 403-410.
34. Leighton, B., Cooper, G.J., DaCosta, C., and Foot, E.A. 1991. Peroxovanadates have full insulin-like effects on glycogen synthesis in normal and insulin-resistant skeletal muscle. Biochem. J. 276: 289-292.
35. Li, S.H., and McNeill, J.H. 2001. In vivo effects of vanadium of GLUT-4 translocation in cardiac tissue of STZ-diabetic rats. Mol. Cell. Biochem. 212: 121-129.
36. Liem, D.A., Gho, C.C., Gho, B.C., Kazim, S., Manintveld, O.C., Verdouw, P.D., and, Duncker, D.J. 2004. The tyrosine phosphatase inhibitor bis(maltolato)-oxovanadium attenuates myocardial reperfusion injury by opening K+ATP channels. J. Pharmacol. Exp. Ther. 309: 1256-1262.
37. Marzban, L., Bhanot, S., and McNeill, J.H. 2001. In vivo effects of insulin and bis(maltolato)oxovanadium (IV) on PKB activity in the skeletal muscle and liver of diabetic rats. Mol. Cell. Biochem. 223: 147-157.
38. Mohammad, A., Sharma, V., and McNeill, J.H. 2002. Vanadium increases GLUT4 in diabetic rat skeletal muscle. Mol. Cell. Biochem. 233: 139-143.
39. Molero, J.C., Perez, C., Martinez, C., et al. Villar, M., Andres, A., Fermin, Y., and Carrascosa, J.M. 2002. Activation of MAP kinase by insulin and vanadate in adipocytes from young and old rats. Mol. Cell. Endocrinol. 189: 77-84.
40. Nakaike, R., Shimokawa, H., Owada, M.K., Tokunaga, O., Yasutake, H., Kishimoto, T. et al. 1996. Vanadate causes synthesis of endothelium-derived NO via pertussis toxin-sensitive G protein in pigs. Am. J. Physiol. 271: H296-H302.
41. Nayler, R.A., and Sparrow, M.P. 1983. Mechanism of vanadate-induced contraction of airways smooth muscle of the guinea-pig. Br. J. Pharmacol. 80: 163-172.
42. Nechay, B.R. 1984. Mechanisms of action of vanadium. Annu. Rev. Pharmacol. Toxicol. 24: 501-524.
43. Noda, C., Masuda, T., Sato, K., Ikeda, K., Shimohama, T., Matsuyama, N., and Izumi, T. 2002. Vanadate improves cardiac function and myocardial energy metabolism in diabetic rat hearts. Jpn. Heart J. 44: 745-757.
44. Olson, A.L., and Pessin, J.E. 1996. Structure, function and regulation of the mammalian facilitative glucose transporter gene family. Annu. Rev. Nutr. 16: 235-256.
45. Ozaki, H., and Urakawa, N. 1980. Effect of vanadate on mechanical responses and Na-K pump in vascular smooth muscle. Eur. J. Pharmacol. 68: 339-347.
46. Pandey, S.K., Chiasson, J.L., and Srivastava, A.K. 1995. Vanadium salts stimulate mitogen-activated protein (MAP) kinases and ribosomal S6 kinases. Mol. Cell. Biochem. 153: 69-78.
47. Pandey, S.K., Anand-Srivastava, M.B., and Srivastava, A.K. 1998. Vanadyl sulfate-stimulated glycogen synthesis is associated with activation of phosphatidylinositol 3-kinase and is independent of insulin receptor tyrosine phosphorylation. Biochemistry, 37: 7006-7014.
48. Pandey, S.K., Theberge, J.F., Bernier, M., and Srivastava, A.K. 1999. Phosphatidylinositol 3-kinase requirement in activation of the ras/c raf-1/MEK/ERK and p70s6k signaling cascade by the insulinomimetic agent vanadyl sulfate. Biochemistry, 38: 14 667-14 675.
49. Peters, K.G., Davis, M.G., Howard, B.W., Pokross, M., Rastogi, V., Diven, C. et al. 2003. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component. J. Inorg. Biochem. 96: 321-330.
50. Posner, B.I., Faure, R., Burgess, J.W., Beavan, A.P., Lachance, D., Zhang-Sun, G., Fantus, I.G., Ng, J.B., Hall, D.A., Lum, B.S., and Shaver, A. 1994. Peroxo-vanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J. Biol. Chem. 269: 4596-4604.
51. 2+ changes in a vascular smooth muscle cell line. Am. J. Physiol. 265: H281-H288.
52. Ramasarma, T., and Crane, F.L. 1981. Does vanadium play a role in cellular regulation? Curr. Top. Cell. Regul. 20: 247-301.
53. St-Louis, J., Sicotte, B., Breton, E., and Srivastava, A.K. 1995. Contractile effects of vanadate on aorta rings from virgin and pregnant rats. Mol. Cell. Biochem. 153: 145-150.
54. Sanchez-Ferrer, C.F., Marin, J., Lluch, M., Valverde, A., and Salaices, M. 1988. Actions of vanadate on vascular tension and sodium pump activity in cat isolated cerebral and femoral arteries. Br. J. Pharmacol. 93: 53-60.
55. Sandirasegarane, L., and Gopalakrishnan, V. 1995. Vanadate increases cytosolic free calcium in rat aortic smooth muscle cells. Life Sci. 56: PL169-PL174.
56. Sekar, N., Li, J., and Shechter, Y. 1996. Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research Crit. Rev. Biochem. Mol. Biol. 31: 339-359.
57. Shafrir, E., Spielman, S., Nachliel, I., Khamaisi, M., Bar-On, H., and Ziv, E. 2001. Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil. Diabetes Metab. Res. Rev. 17: 55-66.
58. Shechter, Y. 1990. Insulin-mimetic effects of vanadate: Possible implications for future treatment of diabetes. Diabetes, 39: 1-5.
59. Shepherd, P.R., Withers, D.J., and Siddle, K. 1998. Phosphoinosite 3-kinase: the key switch mechanism in insulin signaling. Biochem. J. 333: 471-490.
60. Shimada, T., Shimamura, K., and Sunano, S. 1986. Effects of sodium vanadate on various types of vascular smooth muscles. Blood Vessels 23: 113-124.
61. Shimoni, Y., Severson, D., and Ewart, H.S. 2000. Insulin resistance and the modulation of rat cardiac K(+) currents. Am. J. Physiol. 279: H639-H649.
62. Srivastava, A.K. 1995a. Potential use of vanadium compounds in the treatment of diabetes mellitus. Exp. Opin. Invest. Drugs 4: 525-536.
63. Srivastava, A.K. 1995b. Protein tyrosine phosphorylation in cardiovascular system. Mol. Cell. Biochem. 149/150: 87-94.
64. Srivastava, A.K., and Mehdi, M.Z. 2004. Insulino-mimetic and anti-diabetic effects of vanadium compounds. Diabetic Med. In press.
65. Srivastava, A.K., and St-Louis, J. 1997. Smooth muscle contractility and protein tyrosine phosphorylation. Mol. Cell. Biochem. 176: 47-51.
66. Steifen, R.P., Passinani, M.B., Clough, D.L., Huot, S.J., Muldoon, S.M., and Haddy, F.J. 1981. Effect of prolonged dietary administration of vanadate on blood pressure in the rat. Hypertension, 3: 1173-1178.
67. Stern, A., Yin, X., Tsang, S.S., Davison, A., and Moon, J. 1993. Vanadium as a modulator of cellular regulatory cascades and oncogene expression. Biochem. Cell Biol. 71: 103-112.
68. Sunano, S., Kato, S., Moriyama, K., and Shimamura, K. 1988. Influences of sodium on the contractile action of vanadate in depolarized vas deferens and ureter of the guinea-pig. Arch. Int. Pharmacodyn. Therap. 293: 196-208.
69. Swarup, G., Cohen, S., and, Garbers, D.L. 1982. Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem. Biophys. Res. Commun. 107: 1104-1109.
70. Takeuchi, K., McGowan, F.X., Glynn, P., Jr., Moran, A.M., Rader, C.M., Cao-Danh, H., and del Nido, P.J. 1998. Glucose transporter upregulation improves ischemic tolerance in hypertrophied failing heart. Circulation, 98: II-234-II-241.
71. Tanti, J.F., Grillo, S., Gremeaux, T., Coffer, P.J., Obberghen, E.U., and Marchand-Brustel, Y.L. 1997. Potential role of protein kinase B in glucose transporter 4 translocation in adipocytes. Endocrinology, 138: 2005-2010.
72. Tardif, A., Julien, N., Pelletier, A., Thibault, G., Srivastava, A.K., Chiasson, J.-L., and Coderre, L. 2001. Chronic exposure to β- hydroxybutyrate impairs insulin action in primary cultures of adult cardiomyocytes. Am. J. Physiol. 281: E1205-E1212.
73. Tardif, A., Julien, N., Chiasson, J.L., and Coderre, L. 2003. Stimulation of glucose uptake by chronic vanadate pretreatment in cardiomyocytes requires PI 3-kinase and p38 MAPK activation. Am. J. Physiol. 284: E1055-E1064.
74. Tsiani, E., Bogdanovic, E., Sorisky, A., Nagy, L., and Fantus, I.G. 1998. Tyrosine phosphatase inhibitors, vanadate and pervanadate, stimulate glucose transport and GLUT translocation in muscle cells by a mechanism independent of phosphatidylinositol 3-kinase and protein kinase C. Diabetes, 47: 1676-1686.
75. Yuen, V.O., Orvig, C., Thompson, K.H., and McNeill, J.H. 1993. Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis (maltolato) oxo-vanadium (VI). Can. J. Physiol. Pharmacol. 71: 270-276.
76. Yuen, V.O., Pederson, R.A., Dai, S., Orvig, C., and McNeill, J.H. 1996. Effects of low and high dose administration of bis-(maltolato)oxovanadium(IV) on fa/fa Zucker rats. Can. J. Physiol. Pharmacol. 74: 1001-1009.